Fastest
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →https://www.patsnap.com/resources/blog/rd-blog/protein-chromatography-load-optimization-patent-landscape/ · Patsnap · data cut-off 2026-07-31 · downloaded from the live page
Patent Landscape · Protein Chromatography Load OptimizationProtein Chromatography Load Optimization Patents: Who Leads and Where the Field Is Open
- Filings concentrate modestly at the top. the five most active filers account for 14.8% of all 4,236 records, and the ranked ten hold 23.8% — a leadership cluster, not a monopoly.
- Filing activity has cooled from its 2020 peak. confirmed-year filings fell from 113 in 2021 to 75 in 2024, a 34% decline, though 2025-26 figures are still incomplete due to publication lag.
- Peptide and protein claims dominate the class mix. C07K appears in 73.2% of records, more than double the share of the separation-process class B01D at 40.9%, showing most claims sit on molecule handling rather than hardware.
4,236
Published Records
15%
Top-5 Share of All Records
-34%
Filing Growth 2021→2024
US
Leading Jurisdiction
Filing growth compares 2021 (113 records) with 2024 (75) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 4,236 records in scope (CR5), not by the ranked leaders only.
Published byPatsnap Research··7 min readSourced from Patsnap Eureka
Field Overview
What this landscape covers
Protein chromatography load optimization sits at the intersection of downstream bioprocessing and separation engineering: claims here cover how much feed material a resin bed can absorb, how fast it can be run, and how feed conditions like pH and conductivity affect capture. The search scope combines affinity and chromatographic purification terms with load-specific parameters — load density, residence time, breakthrough curve, binding capacity — against the core classification codes for separation apparatus, peptide chemistry and enzyme engineering.
The 4,236 records in scope span 2015 through mid-2026, filed principally through the United States, European and PCT routes, with meaningful volume also reaching Australian, Canadian and Israeli offices. Because publication lags filing by roughly 18 months, the most recent one to two years understate real filing activity.
Filing volume and receiving-office distribution, 2015-2026
Source: Patsnap Eureka. Assignee ranking and totals. Derived from a Patsnap search on Protein Chromatography Load Optimization covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Filing Data
Filing trend and technology composition
The dataset's own numbers set the boundaries for any claim made about this field: where filings peaked, how concentrated ownership is, and which classification codes actually carry the volume.
A 2020 peak followed by a confirmed pullback
Filings ran from 164 in 2017 to a peak of 174 in 2020, then declined on a confirmed basis from 113 in 2021 to 75 in 2024 — a 34% drop across that three-year window. Figures for 2025 and 2026 are still filling in and should not be read as a continuation of that decline.
Molecule claims outweigh hardware claims
C07K (peptides and proteins) touches 73.2% of the 4,236 records, with C12N (microorganisms and genetic engineering) at 45.3% and B01D (separation processes) at 40.9%. Because records often carry several IPC codes, these shares add to more than 100%; the pattern nonetheless shows claim density is heaviest around the molecule and its production route, not the separation hardware itself.
Shares are the percentage of the 4,236 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Source: Patsnap Eureka. Filing trend and technology composition. Derived from a Patsnap search on Protein Chromatography Load Optimization covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.
Go deeper on Protein Chromatography Load Optimization with Eureka
This page is one run against one query. Ask Eureka your own question about protein chromatography load optimization and every answer comes back with the patent numbers behind it.
Try EurekaRepresentative Filing
A representative claim in the field
Representative Record
CA2995385A1 — Purification of FKBP-type peptidyl-prolyl cis-trans isomerase (FkpA) and its use in producing recombinant polypeptides
GENENTECH, INC.
The filing describes methods for producing FkpA polypeptides at very high purity, plus ultrapure FkpA for use in immunoassays confirming its removal from bacterially produced biologics. It also covers purification of polypeptides — including multispecific antibodies — made in bacteria that overexpress one or more chaperones, using affinity chromatography, mixed-mode chromatography and hydrophobic interaction chromatography in combination.Filed by Genentech, Inc., dated 2017-02-23.
View full recordMost-cited records in this landscape
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO1999064619A2 | Novel mannanases | 813 |
| 2 | WO2004003186A2 | Subtilases and subtilase variants having altered immunogenicity | 794 |
| 3 | US20050100543A1 | Multivalent carriers of bi-specific antibodies | 727 |
| 4 | US6175409B1 | Flow-injection analysis and variable-flow light-scattering methods and apparatus for characterizing polymers | 677 |
| 5 | WO1992014843A1 | Aptamer specific for biomolecules and method of making | 609 |
| 6 | US5059654A | Affinity matrices of modified polysaccharide supports | 486 |
| 7 | US6260407B1 | High-temperature characterization of polymers | 477 |
| 8 | US6406632B1 | Rapid characterization of polymers | 459 |
| 9 | US6566114B1 | Mannanases | 429 |
| 10 | US6294388B1 | Indirect calibration of polymer characterization systems | 386 |
Citation counts favour older records inside any searched corpus and should be read as a signal of influence, not current relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Source: Patsnap Eureka. Citation counts and representative records. Derived from a Patsnap search on Protein Chromatography Load Optimization covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Run it yourself
Put your own technology through the same analysis
Where to run it
For builders
MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Landscape Insights
What the numbers mean for a filing decision
Three patterns recur across the dataset: a moderate leadership cluster, a technology mix weighted toward molecule handling, and a filing curve that peaked several years ago on confirmed data.
Concentration
14.8%
of 4,236 records held by the top 5
Leadership is present but not dominant
The five most active filers combine for 14.8% of all records in scope, and the ranked ten reach 23.8%. That leaves the majority of filings spread across a long tail of single- and few-filing entrants, which matters for anyone assessing freedom to operate: no single assignee's portfolio is likely to block an entire load-optimization approach outright.
Based on the 100-company ranked list returned by the dataset.
Filing momentum
-34%
confirmed decline, 2021 to 2024
Confirmed filings have pulled back from the 2020 peak
Filing volume peaked at 174 in 2020 and fell on a confirmed basis from 113 in 2021 to 75 in 2024. That is a real decline within completed years, though 2025-26 counts are still being filled in by publication lag and should not be read as evidence the field has gone quiet.
2025 and later years are partial due to the roughly 18-month publication lag.
Class density
73.2%
of records touch C07K (peptides & proteins)
Claims cluster on the molecule, not the hardware
C07K appears in 73.2% of the 4,236 records, well ahead of B01D separation-process claims at 40.9%. Filing strategy in this space is dominated by molecule- and production-route claims rather than apparatus claims, which shifts where the crowded prior art actually sits.
Shares sum above 100% because records can carry multiple IPC codes.
Filing routes
1,097
records filed via the United States receiving office
US and EPO carry the bulk of filing activity
The United States receiving office accounts for 1,097 records, ahead of Europe (EPO) at 783 and WIPO's PCT route at 451. Australia, Canada and Israel each carry several hundred records, indicating that protection strategies in this field typically extend well beyond the primary US/EU pair.
Counts are per receiving office, not per unique family.
Eureka AI Agent
Looking for what nobody has claimed yet?
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to protein chromatography load optimization, with the prior art for and against each one.
Source: Patsnap Eureka. Co-assignee relationships and derived observations. Derived from a Patsnap search on Protein Chromatography Load Optimization covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Competitive Landscape
Who is filing, and where the gaps sit
The ranked list covers 100 companies counted by records, not a curated top tier — read the concentration figures alongside it rather than treating rank position alone as a signal of strength.
Leader position
195
records held by the top-ranked filer
A clear leader, followed by a shallow drop-off
The leading assignee holds 195 records, more than double the fifth-place filer's 88 and roughly three times the tenth-place filer's 66. The gap from first to fifth place is steep, but the gap from fifth to tenth is comparatively shallow, suggesting a mid-tier cluster of similarly sized programmes rather than a single dominant runner-up.
Ranking counted in records across the 4,236-record dataset.
Co-filing
10
co-assignee pairs identified
Collaboration is limited and concentrated
Only 10 co-assignee pairs appear in the dataset, with the strongest pairing linked at 10 joint records and the next strongest pairs at 5 each. Most filers in this field prosecute independently rather than through joint ventures or shared assignments.
Pair counts reflect shared-assignee records, not licensing agreements.
Recent momentum
0
latest-year filings for several established leaders
Established leaders show little latest-year activity
Several of the more heavily ranked assignees show zero filings in the latest tracked year, some marked at -100% year-on-year. Given the roughly 18-month publication lag, this is at least partly a reporting artifact rather than a confirmed exit from the space, but it does mean recent competitive signal should be read from 2023-24 filings rather than the trailing year.
Momentum figures reflect the single latest tracked year only.
Recent-year filing momentum by assignee
| Assignee | Recent year | YoY |
|---|---|---|
| F. Hoffmann-La Roche AG | 1 | — |
| Regeneron Pharmaceuticals, Inc. | 0 | -100% |
| EMD Millipore Corp. | 0 | -100% |
| Genentech, Inc. | 0 | — |
| Genzyme Corp. | 0 | — |
| AbbVie Inc. | 0 | — |
| UCB Biopharma SPRL | 0 | -100% |
| Cytiva Bioprocess R&D AB (formerly GE Healthcare Bio-Sciences AB, Sweden) | 0 | — |
Source: Patsnap Eureka. Assignee-level momentum. Derived from a Patsnap search on Protein Chromatography Load Optimization covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Next Steps
Where to take this analysis
The figures above set the boundaries of the field. Turning them into a filing or freedom-to-operate decision means drilling into specific claim language and specific assignees.
Check freedom to operate on a specific load parameter
Run the claim language for your target parameter — load density, residence time, feed conductivity — against the ranked assignees' active families rather than relying on the aggregate counts here.
Explore in EurekaTrack the leaders' latest filings directly
Latest-year counts in this dataset are affected by publication lag; monitor filing activity from the ranked leaders directly rather than reading the trailing year as final.
Set up monitoring in EurekaMap white space before drafting new claims
The under-claimed sub-areas identified above are starting points, not conclusions — verify current claim density in each before committing drafting resources.
Search white space in EurekaSource: Patsnap Eureka. Forward-looking reading of the same dataset. Derived from a Patsnap search on Protein Chromatography Load Optimization covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
FAQ
Common questions about this landscape
The dataset's ranked list of 100 companies shows a leader with 195 records, well ahead of the fifth-ranked filer at 88 and the tenth at 66. The top five combined account for 14.8% of all 4,236 records in scope, and the top ten for 23.8%, meaning that even the most active filer holds a minority share of the field. This points to a moderately concentrated but not dominated landscape, so freedom-to-operate work should look across the full ranked list rather than at one company alone.
On confirmed data, filings fell from 113 in 2021 to 75 in 2024, a 34% decline, after peaking at 174 in 2020. However, patent publication typically lags filing by around 18 months, so the lower counts shown for 2025 and 2026 are incomplete rather than evidence of a further drop. The safest reading is a real pullback from the 2020 peak through 2024, with the very latest years still unresolved.
Peptide and protein chemistry claims under C07K appear in 73.2% of the 4,236 records, making it the single most common classification in the dataset. Microorganism and genetic-engineering claims (C12N) follow at 45.3%, and separation-process claims (B01D) at 40.9%. Because a single record can carry multiple IPC codes, these percentages add to more than 100%, but the ordering shows that molecule- and production-route claims outweigh apparatus-specific claims in this field.
Sub-areas such as dynamic breakthrough curve prediction, mixed-mode load sequencing and real-time feed pH correction show comparatively thin claim density relative to the core search terms, based on how the broader dataset clusters around load density and binding capacity. These are starting points for a novelty check rather than confirmed gaps, since claim density can shift quickly once a parameter draws commercial attention. A proper freedom-to-operate search on the specific parameter and jurisdiction is still required before drafting.
The most-cited records in this dataset, several dating to the late 1990s and early 2000s, reflect citation counts accumulated over long periods inside a searched corpus, which structurally favours older filings. High citation counts indicate influence on the field's prior art, not that the underlying technology remains the current commercial standard. Recent-year filing activity and assignee momentum are better indicators of where competitive attention sits today.
Answers are grounded in the same dataset. Derived from a Patsnap search on Protein Chromatography Load Optimization covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Research Protein Chromatography Load Optimization in depth with Eureka
Go past this page: query the whole protein chromatography load optimization corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.